Protalix BioTherapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a dichotomy between a successful regulatory milestone and a stagnating core product business. While the $25 million payment from Chiesi provides a temporary financial victory and a much-needed cash injection, the underlying decline in sales to Pfizer and Fiocruz highlights a fragility in the company's recurring revenue streams. The shift to profitability is a welcome signal for investors, but it is an accounting-driven victory rather than a commercial one. Ultimately, the investment thesis now hinges on whether the EU approval for Elfabrio's E4W dosing can be converted into rapid market adoption. If Chiesi can scale patient acquisition, Protalix will transition into a high-margin royalty machine. However, if the core sales continue to slide and the geopolitical risks in Israel materialize, the current cash pile may simply serve as a buffer against a return to operating losses.